Case Report

Paraneoplastic Erythrocytosis: First Manifestation of a Large Hepatocellular Carcinoma Successfully Treated by Radical Liver Resection and Adjuvant Thalidomide

Carlidia Ortega¹, Grecia Artigas¹*, Ana M Hudson², Mayling Chang³, Álvaro Huete⁴, Marcos Arrese⁵, Paula J Torres⁶, Eduardo Briceno⁷, Martín Dib⁷ and Jorge A. Martinez⁸

¹Division of Surgery, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
²Department of Surgery, Hospital El Salvador, School of Medicine, Universidad de Chile, Santiago, Chile
³Department of Haematology, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
⁴Department of Radiology, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
⁵Department of Gastroenterology, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
⁶Department of Pathology, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
⁷Department of Digestive Surgery, HPB team, University Hospital, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
⁸Visiting International Doctor

ARTICLE INFO

Article history:
Received: 21 September, 2020
Accepted: 12 October, 2020
Published: 23 October, 2020

Keywords:
hepatocellular carcinoma, paraneoplastic syndrome, erythrocytosis, liver resection, thalidomide

ABSTRACT

The paraneoplastic syndromes occur in up to 28% of patients with hepatocellular carcinoma (HCC). Among them, erythrocytosis is reported as just 3.9% of frequency. We describe a 59-year-old male patient with a large HCC in a non-cirrhotic liver presenting with erythrocytosis. Four phlebotomies were performed before radical surgical resection. Extended right hepatectomy was undertaken, proving a unifocal 10.2 X 13 X 6.5 cm, extensively necrotic HCC. There were no postoperative complications, and the patient was discharged on the 6th postoperative day. Adjuvant treatment with thalidomide was indicated for 36 months. We observed a progressive decrease in haemoglobin, haematocrit, EPO, and AFP to normal levels after the surgical procedure. A periodic follow-up with laboratory parameters and CT scan was done for 46 months with no evidence of relapses, until now. This case highlights a rare manifestation of advanced liver cancer; the first documented paraneoplastic erythrocytosis in a large HCC case in Chile was successfully treated by radical liver resection and adjuvant thalidomide.

1. Introduction

Hepatocellular carcinoma (HCC) is the most frequent malignant liver tumor worldwide, ranking at the fourth and sixth positions in terms of mortality (>781,000 deaths) and incidence (>840,000 cases), respectively [1]. In Chile, 1,582 new cases were diagnosed with 1,448 deaths by 2018, becoming the eighth cancer mortality cause [1]. Nowadays, the epidemiological landscape of HCC has suffered significant changes. While chronic viral hepatitis and excessive alcohol consumption have long been described as the main risk factors for HCC, non-alcoholic steatohepatitis (NASH), following the worldwide epidemic of obesity and type 2 diabetes, has become a growing cause of HCC in the western countries [2].

Paraneoplastic syndromes in HCC are not uncommon. They can be found in about 20-28% of cases [3, 4]; most frequent are hypercholesterolemia (24.5%), hypercalcemia (5.3%), and erythrocytosis (3.9%) [5]. Most HCC patients with paraneoplastic syndrome have massive tumors and increased alpha-fetoprotein (AFP) levels in peripheral blood [3, 4]. The erythrocytosis mechanism is not entirely understood, but erythropoietic activity has been demonstrated in HCC patient sera, and erythropoietin (EPO) has been found by immunohistochemical staining in tumor cells but not in normal hepatocytes on surgical specimens [4]. Until now, resection and liver transplantation are the main curative treatments, although a small number of patients achieve to benefit.
Herein, we describe a case of erythrocytosis caused by a massive HCC in a patient with NASH successfully treated by a liver resection with 46 months follow-up without evidence of recurrence.

2. Clinical Case

A 59-year-old male patient was referred to our centre because of perioral cyanosis and asthenia. No weight loss was noted. Laboratory studies showed a red cell count elevated, with a haemoglobin level of 20.3 g/dl, a haematocrit of 62%, and serum erythropoietin (EPO) of 115 mU/ml (normal range 2.6-18.5 mU/ml). Past medical history was uneventful, although a fatty liver was described on ultrasound some years ago. Abdominal ultrasound and MRI scan found a bulky mass in the right hepatic lobe measuring 10.2 x 15.6 x 6.2 cm. The liver showed moderate diffuse steatosis, without signs of cirrhosis (Figure 1). An F18-FDG PET-CT demonstrated marked glucose metabolic activity within the right liver mass with no evidence of distant metastatic foci (Figure 2). Serological tumor markers revealed a raised alpha-fetoprotein level of 36,210 ng/mL, with a CA 19-9 slightly increased (60.8 IU/mL, normal value < 34). Serological tests for hepatitis B and C virus were negative.

**Figure 1:** A) MRI, axial T1 opposed phase image shows a hypointense mass in the right hepatic lobe. Liver presents a moderate diffuse steatosis. B) MRI, axial T1 post gadolinium image in the arterial phase shows little early enhancement in right liver mass (hypovascular). C) MRI, axial T1 post-gadolinium image in late phase shows slight central enhancement in the lesion and delimitation of a peripheral “capsule”.

We programmed four phlebotomies to reduce the thromboembolic risk achieving a haemoglobin level of 14 g/dl with a haematocrit of 45% before a radical resection of the tumor with an open extended right hepatectomy was performed. No RBC packet was required during an uneventful surgical liver resection. There were no postoperative complications, and the patient was discharged on the 6th postoperative day.

**Figure 2:** PET-CT, coronal image of a study carried out with F18-FDG (fluorodeoxyglucose) shows significant glucose hypermetabolism (SUV max = 9.8) in the right liver tumor. No distant metastatic foci were identified.

**Figure 3:** Forty-six months control CT, axial post contrast image shows post-surgical changes of extended right hepatectomy, with compensatory hypertrophy of the left hepatic lobe, which presents extensive diffuse low attenuation determined by steatosis. No solid lesions are seen in the liver parenchyma. No recurrences nor masses are observed in the surgical bed.

Pathological analysis of the surgical specimen, which weighed 1,773 g, showed a unique expansive tumor measuring 10.2 X 13 X 6.5 cm, extensively necrotic. Formalin-fixed tissue was embedded in paraffin, and the sections were firstly stained with Haematoxylin and Eosin (HE). Immunohistochemistry confirmed a moderately differentiated hepatocellular carcinoma confined to the liver lobe. No satellite nodules were found, and microscopic vascular invasion was present. Surgical
Paraneoplastic Erythrocytosis: First Manifestation of a Large Hepatocellular Carcinoma Successfully Treated by Radical Liver Resection and Adjuvant Thalidomide

Paraneoplastic erythrocytosis is a rare manifestation of advanced HCC. Regression of hyperhemoglobinemia after radical oncological resection proved the connection between the two phenomena in our case. Of note, erythrocytosis was the first abnormality found in the described patient, and HCC diagnosis was made after appropriate workup of elevated levels of haemoglobin.

There are different causes of erythrocytosis that can be classified as primary and secondary. Primary Erythrocytosis is the EPOR mutation, a primary congenital entity, and also polycythemia vera, an acquired disease. On the other hand, the acquired secondary etiologies are divide into two groups, those where EPO increase with hypoxia, such as chronic pulmonary disease, hyperventilation syndromes, right to left cardiopulmonary communication, carbon monoxide chronic intoxication, renal artery stenosis and polycystic kidney disease, and without hypoxia, like EPO producing tumors as clear and chromophobe cell renal, hepatocellular, adrenal and parathyroid carcinomas and cerebellar hemangioblastoma among others [7-11].

During the fetal period, the liver is the largest organ secreting EPO. Thus, poor or undifferentiated HCC can liberate this hormone as a de-differentiating tumor cell function. It has been shown that HCC produces EPO by immunohistochemistry, where strong cytoplasmic stains in tumor tissue are seen, but not in non-tumor liver cells [4]. Some of these neoplastic cells produce alpha-fetoprotein (AFP) as well [4, 11]. Local hypoxia in fast-growing tumors could explain EPO secretion in large HCC. A recent report shows the experimental correlation between hypoxic micro-environment and the Hypoxia Inducing Factor (HIF) gene expression inducing EPO secretion in human HCC cells and mice HCC models [12].

Some reports show that patients with NASH-HCC generally have a more advanced presentation of HCC at diagnosis [13, 14], as our patient. A cohort study by Mittal et al. revealed that in comparison to HCV-related HCC, fewer cases of NASH-HCC were diagnosed in early HCC stages or Barcelona Clinic Liver Cancer (BCLC) stage A (5.8% vs. 15.7%, p = 0.04). Also, more NASH-HCC patients were diagnosed in terminal stages or BCLC stage D (19.2% vs. 16.1%, p = 0.04) [14]. In many countries, advanced hepatocellular carcinoma usually presents as abdominal pain or mass with anorexia and weight loss, especially in rural areas of sub-Saharan Africa and Southeast Asia, where radical treatment is scarcely done [4, 5].

Moreover, different studies show that up to 28% of patients with massive HCC have paraneoplastic manifestations. More specifically, up to 3-15% of them have erythrocytosis, although the prevalence varies between studies [4, 5]. Additionally, a correlation has been found between paraneoplastic syndrome and higher levels of AFP. Paraneoplastic HCC manifestations are associated with more advanced stages and larger tumor size [5]. Then, they are adverse prognosis factors in HCC patients undergoing surgical resection.

Radical liver resection is the only definitive treatment for these advanced HCC cases. Liver transplantation (LT), probably the best curative treatment for HCC, is constrained to some restrictive criteria [15, 16], and is the most used treatment of advanced HCC, with reasonable tolerability, with some cases reported with complete remission [22-24]. There is one on-going clinical trial to assess thalidomide as an adjuvant treatment after HCC curative resection with no definitive results yet reported [25]. We decide to prescribe it to our patient because of the predicted poor prognosis of his HCC. At 46 months follow-up, no recurrences have been observed.

3. Discussion

Paraneoplastic erythrocytosis is a rare manifestation of advanced HCC. Regression of hyperhemoglobinemia after radical oncological resection proved the connection between the two phenomena in our case. Of note, erythrocytosis was the first abnormality found in the described patient, and HCC diagnosis was made after appropriate workup of elevated levels of haemoglobin.

During the fetal period, the liver is the largest organ secreting EPO. Thus, poor or undifferentiated HCC can liberate this hormone as a de-differentiating tumor cell function. It has been shown that HCC produces EPO by immunohistochemistry, where strong cytoplasmic stains in tumor tissue are seen, but not in non-tumor liver cells [4]. Some of these neoplastic cells produce alpha-fetoprotein (AFP) as well [4, 11]. Local hypoxia in fast-growing tumors could explain EPO secretion in large HCC. A recent report shows the experimental correlation between hypoxic micro-environment and the Hypoxia Inducing Factor (HIF) gene expression inducing EPO secretion in human HCC cells and mice HCC models [12].

Some reports show that patients with NASH-HCC generally have a more advanced presentation of HCC at diagnosis [13, 14], as our patient. A cohort study by Mittal et al. revealed that in comparison to HCV-related HCC, fewer cases of NASH-HCC were diagnosed in early HCC stages or Barcelona Clinic Liver Cancer (BCLC) stage A (5.8% vs. 15.7%, p = 0.04). Also, more NASH-HCC patients were diagnosed in terminal stages or BCLC stage D (19.2% vs. 16.1%, p = 0.04) [14]. In many countries, advanced hepatocellular carcinoma usually presents as abdominal pain or mass with anorexia and weight loss, especially in rural areas of sub-Saharan Africa and Southeast Asia, where radical treatment is scarcely done [4, 5].

Moreover, different studies show that up to 28% of patients with massive HCC have paraneoplastic manifestations. More specifically, up to 3-15% of them have erythrocytosis, although the prevalence varies between studies [4, 5]. Additionally, a correlation has been found between paraneoplastic syndrome and higher levels of AFP. Paraneoplastic HCC manifestations are associated with more advanced stages and larger tumor size [5]. Then, they are adverse prognosis factors in HCC patients undergoing surgical resection.

Radical liver resection is the only definitive treatment for these advanced HCC cases. Liver transplantation (LT), probably the best curative treatment for HCC, is constrained to some restrictive criteria [15, 16], and is the most used treatment of advanced HCC, with reasonable tolerability, with some cases reported with complete remission [22-24]. There is one on-going clinical trial to assess thalidomide as an adjuvant treatment after HCC curative resection with no definitive results yet reported [25]. We decide to prescribe it to our patient because of the predicted poor prognosis of his HCC. At 46 months follow-up, no recurrences have been observed.

REFERENCES

Paraneoplastic Erythrocytosis: First Manifestation of a Large Hepatocellular Carcinoma Successfully Treated by Radical Liver Resection and Adjuvant Thalidomide


